PROQR THERAPEUTICS EO-,04/ NL0010872495 /
| 2024-04-25 8:01:04 AM | Chg. -0.0560 | Volume | Bid4:34:51 PM | Ask4:39:37 PM | High | Low |
|---|---|---|---|---|---|---|
| 1.8230EUR | -2.98% | 0 Turnover: 0.0000 |
1.7780Bid Size: 1,182 | 1.8340Ask Size: 1,146 | 1.8230 | 1.8230 |
GlobeNewswire
04-23
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held M...
GlobeNewswire
04-22
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
GlobeNewswire
02-15
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate f...
GlobeNewswire
01-19
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet ...
GlobeNewswire
01-05
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
GlobeNewswire
2023-12-08
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Oph...
GlobeNewswire
2023-11-06
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
GlobeNewswire
2023-09-28
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
GlobeNewswire
2023-09-07
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment ...
GlobeNewswire
2022-03-07
ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board
GlobeNewswire
2022-02-24
ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
GlobeNewswire
2022-02-11
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LC...
GlobeNewswire
2022-01-04
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarse...
GlobeNewswire
2021-12-30
ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos C...
